02 August 2019
Visiongain’s new pharma report the 3D Printing for Healthcare Market Report 2019-2029: Forecasts by Products (Syringe Based, Magnetic Levitation, Others), by Technology (Stereolithography (SLA), Fused Deposition Modelling (FDM), Selective Laser Sintering (SLS), Others) and by Application (Dental, Prosthetics and Implants, Tissue and Organ Generation, Others) PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis indicates that the global 3D printing in the Healthcare market will see $872m by spending in 2019.
The 3D printing for healthcare market is emerging due to a large number of developments by the leading market players and the high adoption rate of 3D printing for healthcare. The key players of the world 3D printing for healthcare market are employing novel concepts and ideas, improving manufacturing techniques, and improving the current set of products, besides enhancing their profitability to gain a competitive edge over other market players. Therefore, key players have adopted acquisition & product launch and development as the key developmental strategies to cater to the changing demands of end-users.
The lead analyst of the report said: "The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient. Tailor-made prosthetics, implants and drugs will herald an entirely new system which will eventually be the centrepiece for healthcare systems worldwide. The new and more effective personalised healthcare systems will transition out from the current ‘one size fits all’ approach where effectiveness is not equal from patient to patient. An effort to achieve this more advanced model of healthcare will be the main driver of the 3D printed healthcare product submarket."
The 184-page report contains 65 tables and 95 charts and graphs that add visual analysis in order to explain developing trends within the 3D printing in the Healthcare market. Visiongain provides forecasts for the period 2019-2029 for the leading 3D printing in Healthcare Market.
The 184-page report offers market forecasts and analysis for 18 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering more than 13 companies leading the field in 3D printing in Healthcare and 30 interviews with industry executives and experts from prominent companies.
The 3D printing in Healthcare report will be of value to anyone who wants to better understand the 3D printing in the Healthcare market and its various segments. It will be useful for businesses who wish to comprehend the part of the market better they are already involved in, or those wishing to enter or expand into a different regional or technical part of the 3D printing for healthcare industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, company name produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.